Summary & Overview
HCPCS C2623: Drug-Coated Transluminal Angioplasty Catheter
HCPCS Level II code C2623 represents a drug-coated, non-laser transluminal angioplasty catheter used in endovascular procedures to dilate stenotic vessels while locally delivering a therapeutic agent. This device-level code matters nationally because drug-coated angioplasty catheters are an important option in peripheral and possibly coronary interventions where reducing restenosis risk is a clinical goal. Payer coverage and reimbursement policies for device codes such as C2623 affect access to these technologies and the economics of interventional vascular care.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, sites of service, and typical use cases for the device. The publication also presents benchmarking and coverage themes, notes on where policy updates have recently influenced device utilization, and guidance on common modifier and billing considerations where available.
This national-level summary is designed to inform health policy analysts, billing professionals, and clinical administrative teams about the coding identity and clinical role of C2623, highlight payer relevance, and outline the types of operational and policy insights included in the full publication. Data not available in the input will be indicated within specific sections of the report.
Billing Code Overview
HCPCS Level II code C2623 describes a transluminal angioplasty catheter that is drug-coated, non-laser. The device is intended for use in endovascular procedures to dilate narrowed or obstructed blood vessels while delivering an antiproliferative or other therapeutic agent to the vessel wall.
Service Type: Transluminal angioplasty using a drug-coated catheter
Typical Site of Service: Hospital outpatient department, ambulatory surgical center, or interventional radiology/cardiology suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with symptomatic peripheral arterial disease (PAD) of the lower extremity presenting with lifestyle-limiting claudication or critical limb ischemia (rest pain, non-healing ulcer or gangrene). The patient undergoes vascular evaluation with arterial duplex ultrasound and/or angiography documenting an atherosclerotic focal stenosis or short occlusive lesion in a femoropopliteal or infrapopliteal artery. After diagnostic angiography in an angiography suite or hybrid operating room, the interventionalist performs percutaneous transluminal angioplasty using a drug-coated balloon catheter (C2623) to reduce restenosis risk. The workflow includes vascular access (commonly common femoral artery), lesion crossing with guidewire and catheter, pre-dilation or lesion preparation as indicated, deployment of the drug-coated angioplasty catheter with inflation per manufacturer instructions, post-dilation if needed, completion angiography to confirm flow and absence of complication, hemostasis via closure device or manual compression, post-procedure monitoring in PACU or ambulatory recovery, and discharge with antiplatelet therapy and follow-up vascular clinic visit. Typical site of service is an outpatient interventional radiology or vascular surgery suite, ambulatory surgery center, or hospital outpatient department. The procedure is performed by specialists such as interventional cardiology, interventional radiology, or vascular surgery for patients with arterial atherosclerotic disease threatening limb perfusion or causing significant functional impairment.
Coding Specifications
- For this HCPCS Level II supply code
C2623, the following modifiers are most clinically relevant and commonly applied when reporting the procedure and supplies.
| Modifier |
|---|